Silence Therapeutics plc
Centre Point
103 New Oxford Street
London
WC 1A 1DD
United Kingdom
Tel: 44-0-20-73071620
Fax: 44-0-20-73071680
Website: http://www.silence-therapeutics.com/
158 articles about Silence Therapeutics plc
-
Silence Therapeutics plc's Phase I Atu027 Data Accepted for Presentation at the American Society of Clinical Oncology 2011 Annual Meeting
3/30/2011
-
Silence Therapeutics plc Partner Quark Pharmaceuticals Inc. Announces Results from Phase 2 PF-04523655 Study in Diabetic Macular Edema
3/21/2011
-
Silence Therapeutics plc Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials
2/23/2011
-
Silence Therapeutics plc Provides Year-end Update
12/21/2010
-
Silence Therapeutics plc Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
11/10/2010
-
Silence Therapeutics plc Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
10/20/2010
-
Silence Therapeutics plc Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
9/8/2010
-
Silence Therapeutics plc Adds New Patent to Industry Leading Structural Modification Intellectual Property Portfolio
8/11/2010
-
Silence Therapeutics plc and AstraZeneca PLC Extend siRNA Development Collaboration
7/14/2010
-
Silence Therapeutics plc Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
7/7/2010
-
Silence Therapeutics plc Announces Issuance of New U.S. Patent Broadly Covering Methods for Enhancing Silencing Activity of RNAi Therapeutics
6/9/2010
-
Silence Therapeutics plc Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
5/26/2010
-
Silence Therapeutics plc to Present at Upcoming Investor Conferences
5/11/2010
-
Silence Therapeutics plc Appoints New Vice President of Research
5/5/2010
-
Silence Therapeutics plc Unaudited Preliminary Results for the Year Ended 31 December 2009
4/29/2010
-
Silence Therapeutics plc and AstraZeneca PLC Extend siRNA Delivery Collaboration
4/21/2010
-
Silence Therapeutics plc Appoints Max Herrmann as Chief Financial Officer Appointment Adds Key Financial and Fundraising Experience
4/15/2010
-
Silence Therapeutics plc and Dainippon Sumitomo Pharma Co., Ltd. Expand siRNA Delivery Collaboration
3/30/2010
-
Silence Therapeutics plc Receives Notice of Allowance for RNA Interference (RNAi) Patent Covering Novel Cancer Target
2/8/2010
-
Silence Therapeutics plc to Present at 12th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference
2/5/2010